Charcot neuro-osteoarthropathy (CN) is one of the most consequential — and most frequently missed — complications of diabetes-related peripheral neuropathy. In a foot that has lost protective sensation, inflammation triggers accelerated bone resorption, and continued walking on that inflamed foot progressively destroys joints. The result can be a rigid, collapsed deformity that ulcerates, becomes infected, and ends in amputation. What makes CN clinically distinctive is that the window in which the damage can be limited is measured in weeks, and the presentation during that window is deceptively unremarkable.
Why the Diagnosis Is So Often Delayed
The active phase of CN typically presents as a unilateral warm, red, swollen foot in a person with neuropathy — often with little or no pain, and frequently with no memory of a specific injury. That picture is easily attributed to cellulitis, gout, deep vein thrombosis, or a sprain. The 2023 International Working Group on the Diabetic Foot (IWGDF) guideline on active CN, developed by Wukich and colleagues using GRADE methodology, emphasises that the diagnosis should be suspected on clinical grounds in any neuropathic patient presenting with a warm, swollen foot, and that treatment should begin on suspicion rather than waiting for radiographic confirmation. Plain radiographs are frequently normal in the earliest stage; MRI detects bone marrow oedema and subtle stress injury well before X-ray changes appear.
The differential that causes the most difficulty is osteomyelitis. Both can produce a hot, swollen foot with fragmented-looking bone on imaging in a patient with neuropathy. Pham and colleagues described three cases in which post-surgical swelling and radiographic fragmentation raised concern for bone infection; all three were in fact Charcot events and resolved with immobilisation and offloading alone, without antibiotics or further surgery. Distinguishing the two matters because the treatments diverge sharply — one calls for casting, the other for antimicrobial therapy and often bone resection.
Offloading and Immobilisation Remain the Foundation
Once active CN is identified, the accepted first-line treatment is immobilisation in a total contact cast (TCC) or equivalent non-removable device, continued until the foot has cooled and the bones have consolidated. This is not a brief intervention. In the randomised trials pooled by Rastogi, Bhansali and Jude, median time to clinical remission with casting alone was approximately 16.8 weeks — roughly four months of continuous immobilisation.
Traditional practice has also required strict non-weight-bearing during that period, which is difficult for older patients, those with obesity, and anyone with limited upper-body strength. A 2024 systematic review by Prem and colleagues examined this assumption directly. Across five studies and 158 patients, allowing weight-bearing within a total contact cast did not appear to compromise healing, and no comparative trial has established that non-weight-bearing is superior. The authors concluded that the evidence supporting mandatory non-weight-bearing is limited, and that permitting weight-bearing carries real advantages for independence and quality of life. This remains an area where practice varies and randomised data are still needed.
What Drug Therapy Does and Does Not Add
Because CN involves osteoclast-driven bone resorption — with RANK/RANK-L signalling implicated in its pathophysiology, as reviewed by Cellier — anti-resorptive agents such as bisphosphonates and denosumab have been trialled as adjuncts. The meta-analysis by Rastogi and colleagues found that adding anti-resorptive or anti-inflammatory drugs to casting did not shorten time to remission; pooled median remission was 18.5 weeks with pharmacotherapy versus 16.8 weeks with casting alone. Modest reductions in foot temperature and alkaline phosphatase were observed, but these did not translate into faster clinical resolution. On current evidence, no drug therapy substitutes for adequate offloading.
Deformity, Surgery, and the Long Tail of the Disease
When immobilisation fails, or when the foot has already collapsed into a deformity that cannot be safely accommodated in footwear, reconstruction is considered. Contemporary approaches favour the “superconstruct” principle described by Sammarco and colleagues: extending fusion beyond the zone of injury, resecting bone aggressively enough to correct alignment without over-tensioning the soft tissues, using stronger-than-usual implants, and positioning fixation to maximise mechanical stability. Cellier’s 2025 review of hindfoot and ankle Charcot notes that earlier and more aggressive surgical intervention in appropriately selected patients has been associated with improved quality of life and lower amputation rates, though complication rates remain high and the surgery is technically demanding.
The population-level picture underscores why early recognition matters. Analysing Texas hospital discharge data from 2006 to 2016, Cole and Jupiter found rising age-standardised rates of CN among people with diabetes, alongside increases in both minor and major amputations in this group.
Clinical Summary
A warm, swollen, often painless foot in a person with diabetic neuropathy should be treated as active Charcot neuro-osteoarthropathy until proven otherwise. Plain films may be normal; MRI is the more sensitive early test, and osteomyelitis is the key differential. Immobilisation and offloading — typically a total contact cast for around four months — remain the foundation of treatment, while the requirement for strict non-weight-bearing is less well supported than long assumed. Anti-resorptive drugs have not been shown to shorten remission. Surgical reconstruction is reserved for failed conservative management or established deformity, and carries substantial complication risk.
References
- Wukich DK, Schaper NC, Gooday C, et al. Guidelines on the diagnosis and treatment of active Charcot neuro-osteoarthropathy in persons with diabetes mellitus (IWGDF 2023). Diabetes/Metabolism Research and Reviews. 2023;40(3):e3646. doi:10.1002/dmrr.3646
- Prem R, Vignaraja V, Lewis T, Budair B. Weight bearing versus non-weight bearing total contact cast in the management of active Charcot foot: a systematic review. SAGE Open Medicine. 2024;12:20503121241306957. doi:10.1177/20503121241306957
- Rastogi A, Bhansali A, Jude EB. Efficacy of medical treatment for Charcot neuroarthropathy: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetologica. 2021;58(6):687-696. doi:10.1007/s00592-020-01664-9
- Cellier N. Management of hindfoot and ankle in Charcot arthropathy. EFORT Open Reviews. 2025;10(6):327-335. doi:10.1530/EOR-2025-0057
- Pham HT, Sanders E, Mendeszoon ER, Tseng W. Charcot neuroarthropathy versus osteomyelitis: a case series. Wounds. 2023;35(6):E203-E208. doi:10.25270/wnds/22063
- Cole KA, Jupiter DC. Charcot neuroarthropathy in diabetic patients in Texas. Primary Care Diabetes. 2024;18(5):533-538. doi:10.1016/j.pcd.2024.06.012
- Sammarco VJ, Sammarco JA, Baratz ME, Sammarco GJ. Midfoot fusion using superconstructs for the Charcot foot: current techniques and complications. Instructional Course Lectures. 2024;73:231-245.
Comments
